]>
IRCT20130311012782N52 IRCT 2021-02-24 Yazd University of Medical Sciences The effect of adding Agomelatine to Escitalopram in the treatment of depression The effect of adding Agomelatine to Escitalopram in the treatment of major depressive disorder 2021-04-04 anticipated 70 Complete https://irct.ir/trial/53913 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation patients between two groups will be done by simple random allocation method. To do this, 70 cards with 35 letters A on them and 35 letters B on the other 35 were prepared and placed in a box and shuffled well. Patients are initially asked to take a card out of the box. Depending on the letter written on the card, patients enter the first group (letter A) or the second group (letter B), Blinding description: The method of blinding is that patients are unaware of the type of medication they are receiving. The drug is prescribed by the researcher, but the outcome of the treatment is reviewed by an experienced psychiatrist who is unaware of the type of medication the patient is receiving. 3 Major Depressive Disorder. Intervention 1: Intervention group 1: Receive 25-50 mg oral Agomelatine of Abidi Pharmaceutical Company as a single daily dose and 10-20 mg of oral Escitalopram made by abidi Pharmaceutical Company as a single daily dose for 12 weeks. Intervention 2: Intervention group 2: Receive 10-20 mg of oral Escitalopram in a single daily dose with placebo, which is prepared similar to agomelatine and is given at the same dose and duration. No - There is not a plan to make this available Justification or reason for not sharing IPD is The plan belongs to a government agency and cannot be shared
public Reza Bidaki
Department of Psychology, Shahid sadoughi hospital, Shohadaye gomnam street
Yazd Iran (Islamic Republic of) 8434193474 +98 35 3726 3733 reza.bidaki111@gmail.com Yazd University of Medical Sciences scientific Reza Bidaki
Department of Psychology, Shahid Sadoughi hospital, Shohadaye gomnam street
Yazd Iran (Islamic Republic of) 8434193474 098 35 37263733 reza.bidaki111@gmail.com Yazd University of Medical Sciences Iran (Islamic Republic of) Major Depressive Disorder Patient consent to participate in the study range age between 18-65 years Minimum literacy Has suitable conditions for completing the questionnaire 18 years 65 years Both Drug addiction Having medical and underlying disease Major changes in diet regimen in recent months Existence of verbal and hearing problems F32: Major Depressive Disorder Treatment - Drugs Treatment - Drugs Intervention group 1: Receive 25-50 mg oral Agomelatine of Abidi Pharmaceutical Company as a single daily dose and 10-20 mg of oral Escitalopram made by abidi Pharmaceutical Company as a single daily dose for 12 weeks Intervention group 2: Receive 10-20 mg of oral Escitalopram in a single daily dose with placebo, which is prepared similar to agomelatine and is given at the same dose and duration. Treatment of Major Depressive Disorder. Timepoint: Every month. Method of measurement: Hamilton questionnaire. Yazd University of Medical Sciences Approved 2019-11-21 Ethics committee of ُShahid Sadoughi University of Medical Sciences Research faculty, Shahid sadoughi University of medical sciences, shohadaye gomnam street Yazd Yazd Iran (Islamic Republic of)